Post-kala-azar dermal leishmaniasis developing in miltefosine-treated visceral leishmaniasis

Indian Journal of Dermatology

Volumn 58, Issue 3, 2013, Pages 241-

  Koley, Sankha ^a   Mandal, Rajesh Kumar ^a   Choudhary, Sanjiv ^b   Bandyopadhyay, Arghya ^c  

^a Department of Dermatology ^*  (India)

^b DATTA MEGHE INSTITUTE OF MEDICAL SCIENCES   (India)

^c NORTH BENGAL MEDICAL COLLEGE   (India)

Author keywords

Miltefosine; Post kala azar dermal leishmaniasis; Visceral leishmaniasis

Indexed keywords

KERATIN; MILTEFOSINE; RECOMBINANT PROTEIN;

ABDOMEN; ADULT; ANEMIA; ANTIMICROBIAL THERAPY; ARM; ARTICLE; CASE REPORT; DEPIGMENTATION; EOSINOPHIL COUNT; ERYTHROCYTE SEDIMENTATION RATE; FACE; FEMALE; FEVER; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPIGMENTATION; IMMUNOAFFINITY CHROMATOGRAPHY; MALE; POST KALA AZAR DERMAL LEISHMANIASIS; SKIN BIOPSY; SKIN LEISHMANIASIS; TREATMENT RESPONSE; TRUNK; VISCERAL LEISHMANIASIS;

EID: 84877103952     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.110848     Document Type: Article

References (11)

1. Das Gupta BM. A note on the parasite of dermal leishmanoid. Indian Med Gaz 1927;62:11-2.
2. Brahmachari UN. A new form of cutaneous leishmaniasis-dermal leishmanoid. Indian Med Gaz 1923;57:1125-7.
3. Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, et al. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am J Trop Med Hyg 2009;80:336-8.
4. Kumar D, Ramesh V, Verma S, Ramam M, Salotra P. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Ann Trop Med Parasitol 2009;103:727-30.
5. Sharma MC, Gupta AK, Verma N, Das VN, Saran R, Kar SK. Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases. J Commun Dis 2000;32:67-8.
6. Rathi SK, Pandhi RK, Chopra P, Khanna N. Post-kala-azar dermal leishmaniasis: A histopathological study. Indian J Dermatol Venereol Leprol 2005;71:250-3.
7. Zijlstra EE, Daifalla NS, Kager PA, Khalil EA, El-Hassan AM, Reed SG, et al. rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin Diagn Lab Immunol 1998;5:717-20.
8. Singh S, Kumari V, Singh N. Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen. Clin Diagn Lab Immunol 2002;9:568-72.
9. Gidwani K, Picado A, Ostyn B, Singh SP, Kumar R, Khanal B, et al. Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin Vaccine Immunol 2011;18:346-8.
10. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
11. Ramesh V, Katara GK, Verma S, Salotra P. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br J Dermatol 2011;165:411-4.